Pangaea Oncology S.A. (PANG) - Total Assets
Based on the latest financial reports, Pangaea Oncology S.A. (PANG) holds total assets worth €29.57 Million EUR (≈ $34.57 Million USD) as of June 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Explore PANG cash flow to debt ratio to assess how comfortably operating cash covers total debt obligations.
Pangaea Oncology S.A. - Total Assets Trend (2013–2024)
This chart illustrates how Pangaea Oncology S.A.'s total assets have evolved over time, based on quarterly financial data. See PANG book value for net asset value and shareholders' equity analysis.
Pangaea Oncology S.A. - Asset Composition Analysis
Current Asset Composition (December 2024)
Pangaea Oncology S.A.'s total assets of €29.57 Million consist of 40.5% current assets and 59.5% non-current assets.
| Asset Category | Amount (EUR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 10.3% |
| Accounts Receivable | €7.68 Million | 23.7% |
| Inventory | €270.64K | 0.8% |
| Property, Plant & Equipment | €0.00 | 0.0% |
| Intangible Assets | €12.92 Million | 39.9% |
| Goodwill | €2.47 Million | 7.6% |
Asset Composition Trend (2013–2024)
This chart illustrates how Pangaea Oncology S.A.'s asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Pangaea Oncology S.A. market cap and net worth.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Pangaea Oncology S.A.'s current assets represent 40.5% of total assets in 2024, an increase from 8.7% in 2013.
- Cash Position: Cash and equivalents constituted 10.3% of total assets in 2024, up from 0.8% in 2013.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 46.0% of total assets, an increase from 0.0% in 2013.
- Asset Diversification: The largest asset category is intangible assets at 39.9% of total assets.
Pangaea Oncology S.A. Competitors by Total Assets
Key competitors of Pangaea Oncology S.A. based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Guangzhou Kingmed Diagnostics Group Co Ltd
SHG:603882
|
China | CN¥9.20 Billion |
|
Shanghai Labway Clinical Laboratory Co Ltd
SHE:301060
|
China | CN¥2.35 Billion |
|
Ningbo MedicalSystem Biotechnology Co Ltd
SHE:300439
|
China | CN¥3.66 Billion |
|
Healius Ltd
AU:HLS
|
Australia | AU$1.77 Billion |
|
Monash Ivf Group Ltd
AU:MVF
|
Australia | AU$510.21 Million |
|
Green Cross Lab Cell Corporation
KQ:144510
|
Korea | ₩565.79 Billion |
|
INIFY LABORATORIES AB
F:WY60
|
Germany | €204.64 Million |
|
Check Cap Ltd
NASDAQ:CHEK
|
USA | $377.00K |
Pangaea Oncology S.A. - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.75 | 1.15 | 1.27 |
| Quick Ratio | 1.72 | 1.07 | 1.14 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | €4.29 Million | €1.12 Million | €1.44 Million |
Pangaea Oncology S.A. - Advanced Valuation Insights
This section examines the relationship between Pangaea Oncology S.A.'s asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.77 |
| Latest Market Cap to Assets Ratio | 1.74 |
| Asset Growth Rate (YoY) | 12.4% |
| Total Assets | €32.41 Million |
| Market Capitalization | $56.33 Million USD |
Valuation Analysis
Above Book Valuation: The market values Pangaea Oncology S.A.'s assets above their book value (1.74x), reflecting positive investor sentiment about the company's future prospects.
Rapid Asset Growth: Pangaea Oncology S.A.'s assets grew by 12.4% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Pangaea Oncology S.A. (2013–2024)
The table below shows the annual total assets of Pangaea Oncology S.A. from 2013 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | €32.41 Million ≈ $37.89 Million |
+12.39% |
| 2023-12-31 | €28.83 Million ≈ $33.71 Million |
+1.61% |
| 2022-12-31 | €28.38 Million ≈ $33.18 Million |
+36.11% |
| 2021-12-31 | €20.85 Million ≈ $24.38 Million |
+21.41% |
| 2020-12-31 | €17.17 Million ≈ $20.08 Million |
+1.75% |
| 2019-12-31 | €16.88 Million ≈ $19.73 Million |
-17.07% |
| 2018-12-31 | €20.35 Million ≈ $23.79 Million |
+7.37% |
| 2017-12-31 | €18.96 Million ≈ $22.16 Million |
+5.68% |
| 2016-12-31 | €17.94 Million ≈ $20.97 Million |
+62.95% |
| 2015-12-31 | €11.01 Million ≈ $12.87 Million |
+30.09% |
| 2014-12-31 | €8.46 Million ≈ $9.89 Million |
+29.43% |
| 2013-12-31 | €6.54 Million ≈ $7.64 Million |
-- |
About Pangaea Oncology S.A.
Pangaea Oncology, S.A., a medical services company, provides a range of services to cancer patients in Spain and the rest of European Union countries. It offers molecular diagnostics, such as mutation analysis in tissue and liquid biopsy, gene amplification and translocation testing, immunohistochemistry and fluorescence in-situ hybridization, and gene expression profiling; clinical trials; in vi… Read more